LyphoMed/Fujisawa
Executive Summary
Under the agreement between the two firms, Fujisawa will purchase 1.5 mil. shares of LyphoMed's common stock at $17.50 per share for a total of $26.25 mil. The companies' joint press release incorrectly cited a stock price of $7.50 per share ("The Pink Sheet" Dec. 10, T&G-3).